Cyproheptadine enhances the IK of mouse cortical neurons through sigma-1 receptor-mediated intracellular signal pathway

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  He, Yan Lin ^a   Zhang, Chun Lei ^a   Gao, Xiao Fei ^a   Yao, Jin Jing ^a   Hu, Chang Long ^a   Mei, Yan Ai ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYPROHEPTADINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR TYPE D2; G PROTEIN COUPLED RECEPTOR TYPE H1; G PROTEIN COUPLED RECEPTOR TYPE H2; G PROTEIN COUPLED RECEPTOR TYPE M; HISTAMINE H1 RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; POTASSIUM CHANNEL KV2.1 ALPHA SUBUNIT; SEROTONIN RECEPTOR; SIGMA 1 OPIATE RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRAIN CORTEX; BRAIN NERVE CELL; CELL STRAIN HEK293; CONTROLLED STUDY; DELAYED RECTIFIER OUTWARD POTASSIUM CURRENT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EMBRYO; ENZYME INHIBITION; ENZYME REGULATION; GENETIC TRANSFECTION; HISTAMINERGIC SYSTEM; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIGAND BINDING; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATCH CLAMP; POTASSIUM CURRENT; RAT; RNA INTERFERENCE; SEROTONINERGIC SYSTEM; WHOLE CELL;

ANIMALS; CEREBRAL CORTEX; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYPROHEPTADINE; ELECTRIC CONDUCTIVITY; EXTRACELLULAR SPACE; HEK293 CELLS; HISTAMINE ANTAGONISTS; HUMANS; INTRACELLULAR SPACE; MICE; NEURONS; POTASSIUM; RECEPTORS, SIGMA; SHAB POTASSIUM CHANNELS; SIGNAL TRANSDUCTION;

EID: 84864249439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041303     Document Type: Article

References (45)

1. Droogmans S, Roosens B, Cosyns B, Degaillier C, Hernot S, et al. (2009) Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study. Am J Physiol Heart Circ Physiol 296: H1940-1948.
2. Spangler DL, Brunton S, (2006) Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis. South Med J 99: 593-599.
3. Goudie AJ, Cooper GD, Cole JC, Sumnall HR, (2007) Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol 21: 179-190.
4. Wooltorton JR, Mathie A, (1995) Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds. Br J Pharmacol 116: 2191-2200.
5. Remy DC, Raab AW, Rittle KE, Engelhardt EL, Scriabine A, et al. (1977) A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogues having furan nuclei fused to the 10,11-vinylene bridge. J Med Chem 20: 836-838.
6. Kotake H, Saitoh M, Ogino K, Hirai S, Matsuoka S, et al. (1987) On the ionic mechanism of cyproheptadine-induced bradycardia in a rabbit sinoatrial node preparation. Eur J Pharmacol 139: 307-313.
7. Mao X, Liang SB, Hurren R, Gronda M, Chow S, et al. (2008) Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood 112: 760-769.
8. Codd EE, Baker J, Brandt MR, Bryant S, Cai C, et al. (2010) Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine. Toxicol Sci 117: 493-504.
9. Hawkins BS, Fischer LJ, (2004) Inhibition of insulin synthesis by cyproheptadine: effects on translation. Toxicol Sci 79: 258-265.
10. Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, et al. (2007) Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol 72: 921-933.
11. Walker, J M, Bowen, W D, Walker, F O, Matsumoto, R R, De Costa, B. and Rice, K C, (1990) Sigma receptors: biology and function. Pharmacol Rev. 42, 355-402.
12. Melishchuk A, Loboda A, Armstrong CM, (1998) Loss of shaker K channel conductance in 0K+ solutions: role of the voltage sensor. Biophys J 75: 1828-1835.
13. Mathie A, Wooltorton JR, Watkins CS, (1998) Voltage-activated potassium channels in mammalian neurons and their block by novel pharmacological agents. Gen Pharmacol 30: 13-24.
14. Wulff H, Castle NA, Pardo LA, (2009) Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8: 982-1001.
15. Liu LY, Hoffman GE, Fei XW, Li Z, Zhang ZH, et al. (2007) Delayed rectifier outward K+ current mediates the migration of rat cerebellar granule cells stimulated by melatonin. J Neurochem 102: 333-344.
16. Misonou H, Mohapatra DP, Park EW, Leung V, Zhen D, et al. (2004) Regulation of ion channel localization and phosphorylation by neuronal activity. Nat Neurosci 7: 711-718.
17. Suh HW, Chung KM, Kim YH, Huh SO, Song DK, (1999) Effects of histamine receptor antagonists injected intrathecally on antinociception induced by opioids administered intracerebroventricularly in the mouse. Neuropeptides 33: 121-129.
18. Klouz A, Sapena R, Liu J, Maurice T, Tillement JP, et al. (2002) Evidence for sigma-1-like receptors in isolated rat liver mitochondrial membranes. Br J Pharmacol 135: 1607-1615.
19. Du J, Haak LL, Phillips-Tansey E, Russell JT, McBain CJ, (2000) Frequency-dependent regulation of rat hippocampal somato-dendritic excitability by the K+ channel subunit Kv2.1. J Physiol 522 Pt 1: 19-31.
20. He YL, Zhan XQ, Yang G, Sun J, Mei YA, (2010) Amoxapine inhibits the delayed rectifier outward K+ current in mouse cortical neurons via cAMP/protein kinase A pathways. J Pharmacol Exp Ther 332: 437-445.
21. Freissmuth M, Boehm S, Beindl W, Nickel P, Ijzerman AP, et al. (1996) Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol 49: 602-611.
22. Cerda O, Trimmer JS, (2011) Activity-dependent phosphorylation of neuronal Kv2.1 potassium channels by CDK5. J Biol Chem 286: 28738-28748.
23. Clineschmidt BV, Hanson HM, McGuffin JC, Lotti VJ, Scriabine A, et al. (1976) Appetite stimulant activity of 3-carboxy-10,11-dihydrocyproheptadine. Arch Int Pharmacodyn Ther 223: 287-300.
24. Holl R, Geiger C, Nambo M, Itami K, Schepmann D, et al. (2009) Structure-affinity-relationship study of bicyclic sigma receptor ligands. Cent Nerv Syst Agents Med Chem 9: 220-229.
25. Hayashi T, Su TP, (2004) Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci U S A 101: 14949-14954.
26. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, et al. (1996) Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A 93: 8072-8077.
27. Soriani O, Foll FL, Roman F, Monnet FP, Vaudry H, et al. (1999) A-Current down-modulated by sigma receptor in frog pituitary melanotrope cells through a G protein-dependent pathway. J Pharmacol Exp Ther 289: 321-328.
28. Kim FJ, Kovalyshyn I, Burgman M, Neilan C, Chien CC, et al. (2010) Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Mol Pharmacol 77: 695-703.
29. Levitt ES, Purington LC, Traynor JR, (2010) Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol Pharmacol 79: 461-471.
30. Zhang H, Cuevas J, (2005) sigma Receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J Pharmacol Exp Ther 313: 1387-1396.
31. Aydar E, Palmer CP, Klyachko VA, Jackson MB, (2002) The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34: 399-410.
32. Tchedre KT, Huang RQ, Dibas A, Krishnamoorthy RR, Dillon GH, et al. (2008) Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci 49: 4993-5002.
33. Renaudo A, L'Hoste S, Guizouarn H, Borgese F, Soriani O, (2007) Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl- channels. J Biol Chem 282: 2259-2267.
34. Misonou H, Thompson SM, Cai X, (2008) Dynamic regulation of the Kv2.1 voltage-gated potassium channel during brain ischemia through neuroglial interaction. J Neurosci 28: 8529-8538.
35. Mohapatra DP, Trimmer JS, (2006) The Kv2.1 C terminus can autonomously transfer Kv2.1-like phosphorylation-dependent localization, voltage-dependent gating, and muscarinic modulation to diverse Kv channels. J Neurosci 26: 685-695.
36. Jiao S, Liu Z, Ren WH, Ding Y, Zhang YQ, et al. (2007) cAMP/protein kinase A signalling pathway protects against neuronal apoptosis and is associated with modulation of Kv2.1 in cerebellar granule cells. J Neurochem 100: 979-991.
37. Mavlyutov TA, Epstein ML, Andersen KA, Ziskind-Conhaim L, Ruoho AE, (2010) The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 167: 247-255.
38. Mavlyutov TA, Epstein ML, Liu P, Verbny YI, Ziskind-Conhaim L, et al. (2012) Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N,N'-dimethyltryptamine forming enzyme, indole-N-methyl transferase. Neuroscience 206: 60-68.
39. Liao Z, Yuan C, Peng K, Xiao Y, Liang S, (2007) Solution structure of Jingzhaotoxin-III, a peptide toxin inhibiting both Nav1.5 and Kv2.1 channels. Toxicon 50: 135-143.
40. Rueff L, Graber JJ, Bernbaum M, Kuzniecky RI, (2008) Voltage-gated potassium channel antibody-mediated syndromes: a spectrum of clinical manifestations. Rev Neurol Dis 5: 65-72.
41. Wua YJ, Dworetzky SI, (2005) Recent developments on KCNQ potassium channel openers. Curr Med Chem 12: 453-460.
42. Stahl SM, (2005) Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 10: 319-323.
43. Goueli BS, Hsiao K, Tereba A, Goueli SA, (1995) A novel and simple method to assay the activity of individual protein kinases in a crude tissue extract. Anal Biochem 225: 10-17.
44. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
45. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.